Hot Sale Pharmaceutical Peptides Pasireotide CAS 396091-73-9

Hot Sale Pharmaceutical Peptides Pasireotide CAS 396091-73-9

Product Name: PASIREOTIDE
Synonyms: PASIREOTIDE;Cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-L-phenylalanyl-(4R)-4-[[[(2-aminoethyl)amino]carbonyl]oxy]-L-prolyl];SOM 230;SOM 320;[(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate;SOM 230;SOM 320;CYCLO((4R)-4-(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-)
CAS: 396091-73-9
MF: C58H66N10O9
MW: 1047.23
EINECS:
Product Categories:
Mol File: 396091-73-9.mol

In April 2012, the European Commission approved pasireotide for the treatment of Cushing’s Disease (CD) in adult patients who have not responded to surgical interventionor forwhomsurgery is not anoption.Pasireotide was approved for the same indication by the US FDA in December of 2012. Pasireotide (also known as SOM230) is a cyclohexapeptide that acts as a somatostatin analogue to inhibit the release of ACTH. Somatostatins are cyclic peptides of 14 and 28 amino acids that play animportant role inregulating endocrineandexocrine release inmany tissues through an inhibitory mechanism. There are five known subtypes of somatostatin receptors (SSTRs). Natural somatostatins bind with high affinity to all five subtypes, however, their therapeutic use is limited by rapid degradation in plasma. Pasireotide arose fromefforts to identify a somatostatinmimetic with long-lasting inhibitory effects. Starting with a 14-amino acid somatostatin peptide, a systematic alanine scan revealed residues that were essential for receptor sub-type binding, including key b-turn regions and adjacent residues. Placing the key structural elements as unnatural amino acids in a cyclohexapeptide backbone gave pasireotide.

PASIREOTIDE CAS 396091-73-9
Boiling point 1351.4±65.0 °C(Predicted)
density 1.36±0.1 g/cm3(Predicted)
pka 11.86±0.46(Predicted)
CAS DataBase Reference 396091-73-9

Function and Application of PASIREOTIDE CAS 396091-73-9
As a growth inhibitor analogue that binds to multiple receptors, pasireotide has been shown to be more effective than growth inhibitor analogues such as octreotide and lanreotide in the treatment of acromegaly, carcinoid tumors and Cushing’s disease, both in preclinical trials such as cellular tests and animal studies, and in clinical trials. The results of phase II trial and one phase III trial on pasireotide have confirmed that pasireotide is a new treatment for new or persistent acromegaly and metastatic carcinoid tumors, and may be the first choice of drug treatment for Cushing’s disease.